EP1115422A4 - Verwendung von nicht-peptid wirkstoffen zur behandlung von insulin abhängigen leiden - Google Patents

Verwendung von nicht-peptid wirkstoffen zur behandlung von insulin abhängigen leiden

Info

Publication number
EP1115422A4
EP1115422A4 EP99947113A EP99947113A EP1115422A4 EP 1115422 A4 EP1115422 A4 EP 1115422A4 EP 99947113 A EP99947113 A EP 99947113A EP 99947113 A EP99947113 A EP 99947113A EP 1115422 A4 EP1115422 A4 EP 1115422A4
Authority
EP
European Patent Office
Prior art keywords
treatment
insulin related
peptidyl compounds
related ailments
ailments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99947113A
Other languages
English (en)
French (fr)
Other versions
EP1115422A1 (de
Inventor
Erik Helmerhorst
Brian Scott Plewright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curtin University of Technology
Original Assignee
Curtin University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curtin University of Technology filed Critical Curtin University of Technology
Publication of EP1115422A1 publication Critical patent/EP1115422A1/de
Publication of EP1115422A4 publication Critical patent/EP1115422A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99947113A 1998-09-22 1999-09-17 Verwendung von nicht-peptid wirkstoffen zur behandlung von insulin abhängigen leiden Withdrawn EP1115422A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP6091A AUPP609198A0 (en) 1998-09-22 1998-09-22 Use of non-peptidyl compounds for the treatment of insulin related ailments
AUPP609198 1998-09-22
PCT/AU1999/000786 WO2000016798A1 (en) 1998-09-22 1999-09-17 Use of non-peptidyl compounds for the treatment of insulin related ailments

Publications (2)

Publication Number Publication Date
EP1115422A1 EP1115422A1 (de) 2001-07-18
EP1115422A4 true EP1115422A4 (de) 2003-01-29

Family

ID=3810308

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99947113A Withdrawn EP1115422A4 (de) 1998-09-22 1999-09-17 Verwendung von nicht-peptid wirkstoffen zur behandlung von insulin abhängigen leiden

Country Status (4)

Country Link
EP (1) EP1115422A4 (de)
AU (1) AUPP609198A0 (de)
CA (1) CA2345155A1 (de)
WO (1) WO2000016798A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EP1311262A4 (de) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd Krebstherapie durch kombinationstherapie
CA2423141A1 (en) * 2000-09-27 2002-04-04 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
EP1347755A2 (de) * 2000-10-31 2003-10-01 Merck & Co., Inc. Benzopyrancarbonsäuren-derivate zur behandlung von diabetes und fettstörungen
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
US7087631B2 (en) 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2005041959A1 (en) 2003-10-31 2005-05-12 Janssen Pharmaceutica N.V. Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
FR2879458B1 (fr) * 2004-12-21 2007-07-20 Centre Nat Rech Scient Cnrse Sulfamides et sulfinimides fluores
SI2395002T1 (sl) 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
AU2008335440B2 (en) 2007-12-07 2013-11-07 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8299099B2 (en) 2008-02-28 2012-10-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
WO2010006944A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
ATE538100T1 (de) 2008-07-15 2012-01-15 Hoffmann La Roche Aminotetrahydroindazoloessigsäuren
CN102149677A (zh) 2008-08-15 2011-08-10 霍夫曼-拉罗奇有限公司 联芳基氨基四氢化萘类
WO2010018109A2 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Substituted aminotetralines
RU2011124149A (ru) 2008-11-17 2012-12-27 Ф.Хоффманн-Ля Рош Аг Нафтилуксусные кислоты
JP5373104B2 (ja) 2008-11-17 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｔｈ２アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸
KR101322496B1 (ko) 2008-11-17 2013-10-29 에프. 호프만-라 로슈 아게 나프틸아세트산
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
US9035072B2 (en) 2010-04-22 2015-05-19 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
TW201309698A (zh) 2011-03-18 2013-03-01 Ono Pharmaceutical Co 四氫咔啉衍生物
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
WO2015073231A1 (en) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
PL3424534T3 (pl) 2014-04-15 2021-11-22 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
WO2016081556A1 (en) 2014-11-18 2016-05-26 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) * 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
WO1990015816A1 (en) * 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JP2606915B2 (ja) * 1987-02-25 1997-05-07 ノボ ノルディスク アクティーゼルスカブ 新規インシュリン誘導体
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
KR910700262A (ko) * 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
EP0469084B1 (de) * 1989-04-20 1995-04-05 Mount Sinai School Of Medicine Of The City University Of New York Hepatospezifische insulin-analoga
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) * 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
WO1990015816A1 (en) * 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"[A new salt of metformin proposed in the oral treatment of diabetes: embonate (or pamoate) of metformin]", JOURNEES ANNUELLES DE DIABETOLOGIE DE L'HOTEL-DIEU. FRANCE 1977, 1977, pages 382 - 385, XP000913584, ISSN: 0075-4439 *
AUBERT: "oral antidiabetic...", SCIENCES MEDICALES, vol. 10, no. 47, 1980, pages 31 - 32, XP008010780 *
KLIJN J G ET AL: "Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies.", THE JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. ENGLAND 20 DEC 1990, vol. 37, no. 6, 20 December 1990 (1990-12-20), pages 1089 - 1095, XP008010776, ISSN: 0960-0760 *
LUNDQUIST I: "Islet lysosomal enzyme activities and plasma insulin levels in obese hyperglycemic mice following injection of the lysosomotropic drug suramin.", DIABETES RESEARCH (EDINBURGH, LOTHIAN) SCOTLAND JUL 1985, vol. 2, no. 4, July 1985 (1985-07-01), pages 207 - 211, XP008010803, ISSN: 0265-5985 *
See also references of WO0016798A1 *
SETYONOHAN B (REPRINT) ET AL: "SURAMIN - PHARMACOKINETIC MONITORING, HEMATOLOGICAL AND ANTITUMOR EFFECTS ON RATS BEARING TRANSPLANTABLE PANCREATIC TUMORS", EUROPEAN JOURNAL OF CANCER, (1990) VOL. 26, NO. 2, PP. 184., DR DANIEL DENHOED CANC CTR, DIV ENDOCRINE ONCOL, ROTTERDAM, NETHERLANDS, XP008010849 *

Also Published As

Publication number Publication date
CA2345155A1 (en) 2000-03-30
AUPP609198A0 (en) 1998-10-15
WO2000016798A1 (en) 2000-03-30
EP1115422A1 (de) 2001-07-18

Similar Documents

Publication Publication Date Title
EP1115422A4 (de) Verwendung von nicht-peptid wirkstoffen zur behandlung von insulin abhängigen leiden
IL196301A0 (en) Medicament for the treatment of hapatitis c
HK1041807A1 (en) Cartridge for medical liquid
HUP0103621A3 (en) Fentanyl composition for the treatment of acute pain
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
AU2935200A (en) Compounds for the treatment of obesity
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL148640A0 (en) Processes for the preparation of sumatriptan and related compounds
HUP0101947A3 (en) Combination for the treatment of tumors
IL133760A0 (en) Composition for the treatment of dandruff
AU2566201A (en) Compounds and methods for the treatment of pain
AU1940800A (en) Combination therapy for the treatment of sepsis
HUP0001891A3 (en) Medicament for the treatment of migraine
GB2332849B (en) Apparatus for the treatment of soil
HK1043938A1 (en) Composition for the treatment of psoriasis
GB9904252D0 (en) Composition for the treatment of pain
HUP0300313A3 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
GB9704174D0 (en) Agent for medical treatment
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2420201A (en) Compounds and methods for the treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20021217

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 27/02 B

Ipc: 7A 61K 31/35 B

Ipc: 7A 61K 31/19 B

Ipc: 7A 61K 38/28 A

17Q First examination report despatched

Effective date: 20030926

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050920